CompletedInterventionalPhase 2Last updated Mar 21, 2023

Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)

Overview

ClinicalTrials.gov ID: NCT03109093
Lead Sponsor: Goethe UniversityOTHER
Brief Summary: This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT. The study aims to expand experience generated in previous trials in patients with MRD positive ALL with a focus on additional specific questions.
Study Type

Status

Overall Status: Completed
Start Date: Mar 15, 2017Actual
Primary Completion Date: Aug 15, 2021Actual
Completion Date: Mar 10, 2023Actual

Study Record Dates

First Submitted: Mar 13, 2017
First Submitted that Met QC Criteria: Apr 5, 2017
First Posted: Apr 12, 2017Actual
Last Update Submitted that Met QC Criteria: Mar 17, 2023
Last Update Posted: Mar 21, 2023Actual
Last Verified: Mar 2023

NCT01207388Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT00560794Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT01466179Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT04506086Terminated

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT04044560Terminated

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

NCT04604691Unknown status

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)